Immix Biopharma (IMMX) Interest Expenses (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Interest Expenses data on file, last reported at $356668.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 18.3% year-over-year to $356668.0; the trailing twelve-month figure through Mar 2026 stood at $356668.0 (down 18.3% YoY), and the FY2025 full-year result was $25.3 million, up 60.43% from the prior year.
• Interest Expenses retreated to $356668.0 in Q1 2026, from $25.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $25.3 million in Q4 2025 to a low of $189.0 in Q2 2022.
• A 5-year average of $4.6 million and a median of $1.0 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 99.65% in 2022 and soared 106.56% in 2024, its largest moves.
• Tracing IMMX's Interest Expenses over 5 years: stood at $189.0 in 2022, then jumped by 4037974.6% to $7.6 million in 2023, then surged by 106.56% to $15.8 million in 2024, then soared by 60.43% to $25.3 million in 2025, then sank by 98.59% to $356668.0 in 2026.
• Business Quant data shows IMMX's Interest Expenses at $356668.0 in Q1 2026, $25.3 million in Q4 2025, and $1.5 million in Q3 2025.